Psychedelic Antidepressant Interactions, Frontline Workers Image

Progress for Psychedelic Treatments in Antidepressant Interactions, COVID Distress in Frontline Workers

Share on facebook
Share on twitter
Share on linkedin
Share on email

Tuesday morning saw two large psychedelic biotech developers announce significant research and regulatory advancements for their respective psilocybin pipelines.

MindMed announced the publication of its initial data on the interaction of escitalopram and psilocybin. Escitalopram is a common antidepressant, belonging to the class of those drugs known as selective serotonin uptake inhibitors, or SSRIs. 

The question of how psilocybin, and other psychedelics substances, might interact with conventional antidepressants in a clinical setting has been a major concern for patients, researchers, and regulators alike. Given that two of the primary indications being pursued by the psychedelic research space are major depressive disorder and treatment-resistant depression, providing answers to outstanding safety questions about these drug interactions is crucial to the development of any viable large-scale treatment option.

The randomized, double-blind, placebo-controlled, crossover study, conducted by University Hospital Basel’s Liechti Lab and sponsored by MindMed, found that escitalopram did not alter the pharmacokinetics of psilocin, for which psilocybin is the prodrug. Compared with the placebo group, escitalopram pre-treatment made no significant changes to positive mood effects of psilocybin in patients, but did significantly reduce negative effects like anxiety and adverse cardiovascular reactions. 

“Two key questions arise around the use of psilocybin in patients undergoing antidepressant treatment,” said Prof. Matthias Liechti, the principal investigator of the study. “First, for safety reasons, should a patient stop using antidepressants before receiving psilocybin? Second, if there is no safety risk, will the antidepressant reduce the patient’s response to psilocybin? These results indicate that psilocybin may be dosed during escitalopram treatment without apparent impact on the effect of psilocybin. Thus, the study answers the first question and provides a positive indication for the second.”

The study results highlight important areas for future research. Dr. Miri Halperin Wernli, Executive President of MindMed, added: “If the results are confirmed in subsequent studies, with other substances and in patients rather than healthy individuals, antidepressants may no longer need to be stopped for psilocybin treatment. Further studies are needed with a longer antidepressant pre-treatment time and patients with psychiatric disorders to further define interactions between antidepressants and psilocybin or other psychedelics.”

See Also
Women in Psychedelic Science Graphic

Cybin Receives Regulatory Approval to Expand Psychedelic Therapy Trials for Frontline Workers

The U.S. Food and Drug Administration has granted Cybin Inc. an Investigational New Drug (IND) approval letter to conduct a Phase II-b trial treating frontline healthcare workers suffering from COVID-19-related stress and burnout with psilocybin-assisted psychotherapy.

The investigator-initiated trial will take place in Seattle. The FDA also granted Institutional Review Board (IRB) approval to the University of Washington.

“Throughout the COVID-19 pandemic, nurses, doctors, and healthcare professionals on the frontlines have worked hard to provide care under extremely difficult circumstances. Understandably, under this stress, many frontline healthcare workers have experienced symptoms of depression and burnout. We believe psychedelic medicine, when given with a supportive psychotherapy program like the EMBARK approach, may provide a promising treatment approach to bolster mental health,” said Dr. Alex Belser, Cybin’s Chief Clinical Officer. 

Research on #psilocybin in the State of Oklahoma may soon be streamlined with the filing of two new bills last week by @RepLoganP and @RepDanielPae.

Read the full story here: http://ow.ly/MqbL50HESwF

#oklahoma #oklahomanews #medicine #research

FDA Clears MindMed $MNMD IND for MM-120 in Treatment of Generalized Anxiety Disorder

"FDA clearance leads to first commercial IND for LSD, enabling initiation of Phase 2b dose-optimization trial of MM-120 in early 2022"
https://psilocybinalpha.com/news/fda-clears-mindmed-ind-for-mm-120-in-treatment-of-generalized-anxiety-disorder

Psychedelics don’t cure autism.
Autism doesn’t need a cure.
Autistics, however, COULD use…
relief from feeling inadequate.
Psychedelics bring that love
and with that comes… LOVE 💕

More than 10 million people worldwide live with Parkinson’s Disease. Truffle Report has put together a review of prospective treatments and trials involving #psychedelics from leading institutions like @Yale and the @TrPR_Program.

Full article here: http://ow.ly/CZS650HCEOv

Can you experience #psilocybin withdrawal?

Chemical dependence isn't usually an issue with psychedelics, but it's important to examine your relationship with any substance, particularly one that is fast becoming a mental health fix.

Full article here: http://ow.ly/nq8450HBM8p

Load More...

Related Articles

Scroll To Top